Chao-Hua Yan1, Feng Li1, Yuan-Chen Ma2. 1. Department of Orthopedics, Jiujiang No. 1 People's Hospital Jiujiang 332000, China. 2. Guangdong Academy of Medical Science Guangzhou 510080, China ; Department of Orthopedics, Guangdong General Hospital Guangzhou 510080, China.
Abstract
OBJECTIVE: Plumbagin, a naphthoquinone constituent of Plumbago zeylanica L. (Plumbaginaceae), has been extensively studied for its pharmacological activities and reported to show a good anti-cancer activity in different human cancer cell lines. It is known to exhibit proapoptotic, antiangiogenic and antimetastatic effects in cancer cells. Plumbagin is also known to inhibit NF-κB, JNK (Hsu), PKCε, and STAT-3. However, the anti-proliferatory activity and their core molecular mechanisms have been poorly determined. METHODS: Human osteosarcoma (MG-63) cells were exposed to plumbagin and the anti-proliferative activity was evaluated by MTT assay. The mechanism of action for the growth inhibitory activity of plumbagin on MG-63 cells was evaluated using flow cytometry for cell cycle distribution, and western blot for assessment of accumulation and phosphorylation of potential target proteins. Furthermore, morphology of MG-63 cells was assessed after treatment with Plumbagin. RESULTS: Plumbagin has significantly induced growth inhibition against osteosarcoma MG-63 cells, primarily by S-phase cell cycle arrest which is confirmed by the down regulation of cyclin A and CDK2 protein levels determined by western blot analysis. It was also found that plumbagin has triggered the DNA damage in MG-63 cells, subsequently initiating the arrest in S-phase, which is evident by the up-regulation of phosphorylated p53 and histone. Furthermore, plumbagin resulted in the down-regulation of c-myc protein expression in the MG-63 cells. CONCLUSION: Plumbagin has triggered DNA damage and had induced S-phase arrest in MG-63 cells, suggesting it to be a potential compound in treatment against malignant human osteosarcoma.
OBJECTIVE: Plumbagin, a naphthoquinone constituent of Plumbago zeylanica L. (Plumbaginaceae), has been extensively studied for its pharmacological activities and reported to show a good anti-cancer activity in different humancancer cell lines. It is known to exhibit proapoptotic, antiangiogenic and antimetastatic effects in cancer cells. Plumbagin is also known to inhibit NF-κB, JNK (Hsu), PKCε, and STAT-3. However, the anti-proliferatory activity and their core molecular mechanisms have been poorly determined. METHODS:Humanosteosarcoma (MG-63) cells were exposed to plumbagin and the anti-proliferative activity was evaluated by MTT assay. The mechanism of action for the growth inhibitory activity of plumbagin on MG-63 cells was evaluated using flow cytometry for cell cycle distribution, and western blot for assessment of accumulation and phosphorylation of potential target proteins. Furthermore, morphology of MG-63 cells was assessed after treatment with Plumbagin. RESULTS: Plumbagin has significantly induced growth inhibition against osteosarcoma MG-63 cells, primarily by S-phase cell cycle arrest which is confirmed by the down regulation of cyclin A and CDK2 protein levels determined by western blot analysis. It was also found that plumbagin has triggered the DNA damage in MG-63 cells, subsequently initiating the arrest in S-phase, which is evident by the up-regulation of phosphorylated p53 and histone. Furthermore, plumbagin resulted in the down-regulation of c-myc protein expression in the MG-63 cells. CONCLUSION: Plumbagin has triggered DNA damage and had induced S-phase arrest in MG-63 cells, suggesting it to be a potential compound in treatment against malignant humanosteosarcoma.
Authors: T Shimizu; T Ishikawa; E Sugihara; S Kuninaka; T Miyamoto; Y Mabuchi; Y Matsuzaki; T Tsunoda; F Miya; H Morioka; R Nakayama; E Kobayashi; Y Toyama; A Kawai; H Ichikawa; T Hasegawa; S Okada; T Ito; Y Ikeda; T Suda; H Saya Journal: Oncogene Date: 2010-08-02 Impact factor: 9.867
Authors: Dinis Pedro Calado; Yoshiteru Sasaki; Susana A Godinho; Alex Pellerin; Karl Köchert; Barry P Sleckman; Ignacio Moreno de Alborán; Martin Janz; Scott Rodig; Klaus Rajewsky Journal: Nat Immunol Date: 2012-09-23 Impact factor: 25.606
Authors: Xin-Yi Zheng; Chuan-Yuan Mao; Han Qiao; Xi Zhang; Li Yu; Ting-Yu Wang; Er-Yi Lu Journal: Acta Pharmacol Sin Date: 2017-05-29 Impact factor: 6.150